Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

Researchers from the US have shown that combination therapy with sitagliptin and metformin results in a substantial and additive glycemic improvement in patients with type 2 diabetes. Sitagliptin ...

The latest verdict – in a federal appeals court – has upheld the validity of a key patent on sitagliptin, the active ingredient in Januvia, as well as metformin combinations Janumet and ...

In Part 2, patients were randomized in a 2:1 ratio into two treatment groups (DA-1241 100 mg + 100 mg sitagliptin, or placebo). The primary efficacy outcome was the change in alanine ...

Zydus Lifesciences Ltd., a global innovation driven healthcare company, announced that it has entered into an agreement with CVS Caremark, a CVS Health company to add Zituvio, Zituvimet and Zituvimet ...

These three NDAs of Sitagliptin (base) and combination franchise had been approved by the USFDA earlier. (Image Credits: Pixabay) Zydus Lifesciences Ltd on Tuesday announced that it has entered ...

Find all the commercial and brand names of generic drug called Sitagliptin. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...

Expert Rev Endocrinol Metab. 2008;3(6):691-697. Elimination of sitagliptin occurs primarily via renal excretion (79%) and involves active tubular secretion. Sitagliptin is a substrate for human ...